Sana Biotechnology, Inc.

About Sana Biotechnology, Inc.

Sana Biotechnology aims to lead in creating novel medicines by repairing and controlling genes in cells or replacing missing or damaged cells to solve the underlying causes of many diseases, with a focus on meaningfully improving patient outcomes.

Products & Services

Engineered Cell Therapies:Innovative drug candidates using engineered cells as medicines to deliver unprecedented benefits to patients, targeting diseases like cancer, diabetes, and autoimmune disorders.

Specialties

Engineered Cell Therapies Cellular Biology Gene Repair and Control Therapeutics Development Machine Learning in Biotech engineered cell therapies gene editing cell replacement

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity T: - FT: Equity	A: 69000000 MR: - FA: approximately $69 million FAN: 69000000	D: 2026-05-15 FD: 2026-05-15	2 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 86300000 MR: - FA: approximately $86.3 million FAN: 86300000	D: 2025-08-20 FD: 2025-08-20	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 75000000 MR: - FA: $75.0 million FAN: 75000000	D: 2025-08-06 FD: 2025-08-06	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 189750000 MR: - FA: approximately $189.75 million FAN: 189750000	D: 2024-02-12 FD: 2024-02-12	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 165000000 MR: - FA: $165.0 million FAN: 165000000	D: 2024-02-08 FD: 2024-02-08	4 investors
6	RT: Public Offering T: - FT: Public Offering	A: 125000000 MR: - FA: $125.0 million FAN: 125000000	D: 2024-02-07 FD: 2024-02-07	4 investors

Equity Latest

2026-05-15

$69.0M

2 investors (Pro only)

Underwritten Public Offering 2025-08-20

$86.3M

Public Offering 2025-08-06

$75.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Steve Harr

President and Chief Executive Officer

S

Steve Harr

President and Chief Executive Officer

J

John Gerecitano

Head of Oncology Research and Development

A

Aaron Grossman

Executive Vice President, Chief Legal Officer

G

Gary Meininger

Chief Medical Officer

D

Dhavalkumar Patel

Chief Scientific Officer

View 16 more team members with Pro

Unlock Full Team Directory

Recent News